138 related articles for article (PubMed ID: 28501784)
1. Cellular uptake mechanism and clearance kinetics of fluorescence-labeled glycyrrhetinic acid and glycyrrhetinic acid-modified liposome in hepatocellular carcinoma cells.
Sun Y; Lu J; Yan D; Shen L; Hu H; Chen D
Environ Toxicol Pharmacol; 2017 Jul; 53():46-56. PubMed ID: 28501784
[TBL] [Abstract][Full Text] [Related]
2. Binding effect of fluorescence labeled glycyrrhetinic acid with GA receptors in hepatocellular carcinoma cells.
Sun YQ; Dai CM; Zheng Y; Shi SD; Hu HY; Chen DW
Life Sci; 2017 Nov; 188():186-191. PubMed ID: 28768154
[TBL] [Abstract][Full Text] [Related]
3. The anti-tumor performance of docetaxel liposomes surface-modified with glycyrrhetinic acid.
Li J; Xu H; Ke X; Tian J
J Drug Target; 2012 Jun; 20(5):467-73. PubMed ID: 22577855
[TBL] [Abstract][Full Text] [Related]
4. Hepatocellular carcinoma-targeted effect of configurations and groups of glycyrrhetinic acid by evaluation of its derivative-modified liposomes.
Sun Y; Dai C; Yin M; Lu J; Hu H; Chen D
Int J Nanomedicine; 2018; 13():1621-1632. PubMed ID: 29588589
[TBL] [Abstract][Full Text] [Related]
5. Glycyrrhetinic acid-functionalized mesoporous silica nanoparticles as hepatocellular carcinoma-targeted drug carrier.
Lv Y; Li J; Chen H; Bai Y; Zhang L
Int J Nanomedicine; 2017; 12():4361-4370. PubMed ID: 28652738
[TBL] [Abstract][Full Text] [Related]
6. A wogonin-loaded glycyrrhetinic acid-modified liposome for hepatic targeting with anti-tumor effects.
Tian J; Wang L; Wang L; Ke X
Drug Deliv; 2014 Nov; 21(7):553-9. PubMed ID: 24215357
[TBL] [Abstract][Full Text] [Related]
7. Glycyrrhetinic Acid-Mediated Polymeric Drug Delivery Targeting the Acidic Microenvironment of Hepatocellular Carcinoma.
Zhang J; Zhang M; Ji J; Fang X; Pan X; Wang Y; Wu C; Chen M
Pharm Res; 2015 Oct; 32(10):3376-90. PubMed ID: 26148773
[TBL] [Abstract][Full Text] [Related]
8. Glycyrrhetinic Acid Mediated Drug Delivery Carriers for Hepatocellular Carcinoma Therapy.
Cai Y; Xu Y; Chan HF; Fang X; He C; Chen M
Mol Pharm; 2016 Mar; 13(3):699-709. PubMed ID: 26808002
[TBL] [Abstract][Full Text] [Related]
9. A pH-Responsive Glycyrrhetinic-Acid-Modified Small-Molecule Conjugate for NIR Imaging of Hepatocellular Carcinoma (HCC).
Singh H; Lim JY; Sharma A; Yoon DW; Kim JH; Yang Z; Qu J; Kim J; Lee SG; Kim JS
Chembiochem; 2019 Feb; 20(4):614-620. PubMed ID: 30496637
[TBL] [Abstract][Full Text] [Related]
10. Enhanced targeted delivery of adenine to hepatocellular carcinoma using glycyrrhetinic acid-functionalized nanoparticles in vivo and in vitro.
Wu F; Xue H; Li X; Diao W; Jiang B; Wang W; Yu W; Bai J; Wang Y; Lian B; Feng W; Sun T; Qu M; Zhao C; Wang Y; Wu J; Gao Z
Biomed Pharmacother; 2020 Nov; 131():110682. PubMed ID: 32947204
[TBL] [Abstract][Full Text] [Related]
11. Glycyrrhetinic acid-decorated and reduction-sensitive micelles to enhance the bioavailability and anti-hepatocellular carcinoma efficacy of tanshinone IIA.
Chen F; Zhang J; He Y; Fang X; Wang Y; Chen M
Biomater Sci; 2016 Jan; 4(1):167-82. PubMed ID: 26484363
[TBL] [Abstract][Full Text] [Related]
12. Chemopreventive effect of 18β-glycyrrhetinic acid via modulation of inflammatory markers and induction of apoptosis in human hepatoma cell line (HepG2).
Hasan SK; Siddiqi A; Nafees S; Ali N; Rashid S; Ali R; Shahid A; Sultana S
Mol Cell Biochem; 2016 May; 416(1-2):169-77. PubMed ID: 27116616
[TBL] [Abstract][Full Text] [Related]
13. Glycyrrhetinic Acid triggers a protective autophagy by activation of extracellular regulated protein kinases in hepatocellular carcinoma cells.
Tang ZH; Li T; Chang LL; Zhu H; Tong YG; Chen XP; Wang YT; Lu JJ
J Agric Food Chem; 2014 Dec; 62(49):11910-6. PubMed ID: 25403108
[TBL] [Abstract][Full Text] [Related]
14. 18β-Glycyrrhetinic-acid-mediated unfolded protein response induces autophagy and apoptosis in hepatocellular carcinoma.
Chen J; Zhang ZQ; Song J; Liu QM; Wang C; Huang Z; Chu L; Liang HF; Zhang BX; Chen XP
Sci Rep; 2018 Jun; 8(1):9365. PubMed ID: 29921924
[TBL] [Abstract][Full Text] [Related]
15. Development of Glycyrrhetinic Acid and Folate Modified Cantharidin Loaded Solid Lipid Nanoparticles for Targeting Hepatocellular Carcinoma.
Xu Y; Wang M; Ning S; Yang Z; Zhou L; Xia X
Molecules; 2022 Oct; 27(20):. PubMed ID: 36296377
[TBL] [Abstract][Full Text] [Related]
16. Development of 11-DGA-3-
Zhou L; Zou M; Zhu K; Ning S; Xia X
Molecules; 2019 Aug; 24(17):. PubMed ID: 31450608
[TBL] [Abstract][Full Text] [Related]
17. Glycyrrhetinic acid-modified graphene oxide mediated siRNA delivery for enhanced liver-cancer targeting therapy.
Qu Y; Sun F; He F; Yu C; Lv J; Zhang Q; Liang D; Yu C; Wang J; Zhang X; Xu A; Wu J
Eur J Pharm Sci; 2019 Nov; 139():105036. PubMed ID: 31446078
[TBL] [Abstract][Full Text] [Related]
18. Development of glycyrrhetinic acid-modified stealth cationic liposomes for gene delivery.
He ZY; Zheng X; Wu XH; Song XR; He G; Wu WF; Yu S; Mao SJ; Wei YQ
Int J Pharm; 2010 Sep; 397(1-2):147-54. PubMed ID: 20667672
[TBL] [Abstract][Full Text] [Related]
19. Synthesis and biological evaluation of furoxan-based nitric oxide-releasing derivatives of glycyrrhetinic acid as anti-hepatocellular carcinoma agents.
Lai Y; Shen L; Zhang Z; Liu W; Zhang Y; Ji H; Tian J
Bioorg Med Chem Lett; 2010 Nov; 20(22):6416-20. PubMed ID: 20932754
[TBL] [Abstract][Full Text] [Related]
20. 18-GA-Suc Modified Liposome Loading Cantharidin for Augmenting Hepatic Specificity: Preparation, Characterization, Antitumor Effects, and Liver-Targeting Efficiency.
Zhu K; Zhou L; Zou M; Ning S; Liu S; Zhou Y; Du K; Zhang X; Xia X
J Pharm Sci; 2020 Jun; 109(6):2038-2047. PubMed ID: 32173319
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
